Search our website

Coronavirus

CEPI Boosts ‘Coronavirus X’ Vaccine Search with Expanded VBI Vaccines Deal
December 6th, 2022
VBI Vaccines Announces Initiation of Phase 1 Study of Multivalent Coronavirus Vaccine Candidate, VBI-2901
September 29th, 2022
VBI Vaccines Announces New Data and Progress of VBI-2900, VBI’s eVLP Coronavirus Program
April 5th, 2022
VBI Vaccines Announces New Preclinical Data and Initiation of VBI-2905 Clinical Study Targeting Broadened Immunity Against COVID-19 and Variants of Concern
September 29th, 2021
VBI Vaccines Announces Initial Positive Phase 1 Data for its eVLP Vaccine Candidate Against COVID-19
June 29th, 2021
VBI Vaccines Announces Publication of Preclinical and Challenge Study Data of its eVLP Vaccine Candidate Against COVID-19 (VBI-2902)
April 28th, 2021
CEPI and VBI Vaccines Collaborate to Advance Vaccine Candidates Against COVID-19 Variants
March 10th, 2021
VBI Vaccines Announces Initiation of Enrollment in Adaptive Phase 1/2 Study of Prophylactic COVID-19 Vaccine Candidate, VBI-2902
March 9th, 2021
VBI Vaccines Announces Progress of Coronavirus Vaccine Program
January 21st, 2021
VBI Vaccines to Present at Upcoming Scientific Conferences
September 24th, 2020
VBI Vaccines Announces Preclinical Coronavirus Program Data and Selection of Clinical Candidates with Potential as One-Dose Vaccines
August 26th, 2020
VBI Vaccines Awarded Up to CAD$56 Million Contribution from Canadian Government to Accelerate Coronavirus Vaccine Development
August 5th, 2020
VBI Vaccines Announces Collaboration with the National Research Council of Canada to Develop Pan-Coronavirus Vaccine Candidate Targeting COVID-19, SARS, and MERS
March 31st, 2020

Sign-up for Our Distribution List to Receive the Latest News and Updates from VBI

Sign Up NowArrow
Go top